Understanding current and emerging therapies for HNC

Understanding current and emerging therapies for HNC
Understanding current and emerging therapies for HNC


To start this activity click Next at the bottom of this page

Release date: December 31, 2013

Expiration date: December 31, 2015

Estimated time to complete this activity: 30 minutes

This continuing nursing education activity is provided by the Nurse Practitioner Healthcare Foundation (NPHF).

NPHF is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. 

Statement of need: Cancers that develop in and around the oral mucosa are collectively referred to as head and neck cancers (HNCs). Although the major risk factors (tobacco use and excessive alcohol use) and most prevalent population (persons older than 60 years) are well-known, a new patient demographic is emerging. A recently identified association between HNCs, particularly oropharyngeal cancer, and human papillomavirus (HPV) infection is reflected in increased incidence of oropharyngeal cancer in younger patients with no other risk factors. In addition, HPV status has an impact on response to treatment. This activity can help oncology nurses refresh their knowledge of the risks and treatments for HNCs, and keep pace with emerging trends in patient populations and new treatment approaches.

Target audience: This activity has been designed to meet the educational needs of registered nurses and nurse practitioners involved in the management of patients with cancer.

Educational objectives:

• Explain the impact of HPV infection on the incidence of head and neck cancer

• Explain the staging system used for head and neck cancer

• Describe the multimodal approach to managing head and neck cancer

Accreditation statement: This continuing nursing education activity is provided by the Nurse Practitioner Healthcare Foundation (NPHF).

NPHF is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation statement: Free continuing nursing education credit of 0.5 is available, of which 0.25 is pharmacology. After reading the article, go to mycme.com to register, take the posttest, and receive a certificate. A score of 80% is required to pass.

Please note that the posttest is available only on myCME.com. The article may also be viewed at OncologyNurseAdvisor.com and on the Nurse Practitioner Healthcare Foundation Web site: www. ­nphealthcarefoundation.org. For more information, contact Fiona Shannon at fiona@­nphealthcarefoundation.org. 

Disclosure of conflicts of interest: The Nurse Practitioner Healthcare ­Foundation (NPHF) assesses conflict of interest with its instructors, planners, reviewers, and other ­individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by NPHF for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. NPHF is committed to providing its learners with high quality CE activities and related ­materials that promote improvements or quality in health care.

The faculty: Donald R. Fleming, MD, reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.

The planners, reviewers, and staff: Fiona J. Shannon, MHS, FNP; Joyce Pagan; Kristen Childress, DNP, ARNP; Connie Morrison-Hoogstede, MN, ANP, AOCNP; and Genean M. Page, RN, OCN, reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.

Disclaimer: The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of or imply ­endorsement by Nurse Practitioner Healthcare Foundation, American Nurses Credentialing Center, or Haymarket Media Inc.

As this article contains only a review, participants have an implied responsibility to use this newly acquired information while also consulting other appropriate sources of information in order to gain full understanding of the topic.

NEXT


HOW TO TAKE THE POST-TEST: To obtain CE credit, please click here after reading the article to take the post-test on myCME.com.


Page 1 of 4
Loading links....
You must be a registered member of ONA to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs